An adenosine A(1) receptor antagonist whose development was discontinued in June 2009 after poor results in heart failure trials as of 2010 unpublished. It facilitates immediate diuresis and preserves renal function in acute decompensated heart failure at the risk of seizures.
- ↑ Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Journal of cardiac failure. 2008 Oct; 14(8):631-40.(Link to article – subscription may be required.)
- ↑ Slawsky MT, Givertz MM. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert opinion on pharmacotherapy. 2009 Feb; 10(2):311-22.( Link to article – subscription may be required.)